^
    Back
    Association details:
    Biomarker:Chr del(17p)
    Cancer:Chronic Lymphocytic Leukemia
    Drug:Rituxan (rituximab) (CD20 inhibitor) +
    Campath (alemtuzumab) (CD52 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma:…CLL/SLL with del(17p)/TP53 mutation...Other recommended regimens...Alemtuzumab ± rituximab...
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer
    Title:

    Alemtuzumab by Continuous Intravenous Infusion Followed by Subcutaneous Injection Plus Rituximab in the Treatment of Patients With Chronic Lymphocytic Leukemia Recurrence

    Published date:
    05/15/2010
    Excerpt:
    CONTRADICTING EVIDENCE:...a study was designed exploring continuous intravenous infusion (civ) followed by subcutaneous (sc) alemtuzumab together with weekly iv rituximab in patients with previously treated CLL....The 1 patient with deletion of chromosome 17p achieved a PR, but developed disease progression soon thereafter so that he had to be taken off study at the end of 2 cycles.
    DOI:
    10.1002/cncr.24958